<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Rituximab is a monoclonal antibody that targets the uniquely expressed B-cell CD20 receptor </plain></SENT>
<SENT sid="1" pm="."><plain>Although recently approved for treatment of follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, the intracellular events that occur when rituximab binds to CD20 are largely unknown </plain></SENT>
<SENT sid="2" pm="."><plain>Quantitative proteomic analysis of B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>-derived cells exposed to rituximab was performed </plain></SENT>
<SENT sid="3" pm="."><plain>Differentially expressed proteins belonged to functional groups involved in migration, <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, calcium-induced signaling, ubiquitination, and components of the phosphoinositol and NF-kappaB pathways </plain></SENT>
<SENT sid="4" pm="."><plain>Our studies reveal the proteomic consequences of rituximab treatment and provide novel insights into the mechanism of action of the drug in susceptible B-cell <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> </plain></SENT>
</text></document>